{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:57:23Z","timestamp":1793041043281,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.esmogo.2024.100095","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T09:21:26Z","timestamp":1728379286000},"page":"100095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Z.A.","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-1521","authenticated-orcid":false,"given":"S.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1422","authenticated-orcid":false,"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-3983","authenticated-orcid":false,"given":"A.","family":"Gnanasakthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Majer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-4361","authenticated-orcid":false,"given":"A.","family":"Jamotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-K.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmogo.2024.100095_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100095_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","article-title":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","volume":"20","author":"Thrift","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100095_bib3","first-page":"520","article-title":"Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy","volume":"31","author":"Pape","year":"2023","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100095_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4143\/crt.2018.073","article-title":"Treatment patterns and changes in quality of life during first-line palliative chemotherapy in Korean patients with advanced gastric cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100095_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7903","key":"10.1016\/j.esmogo.2024.100095_bib8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"issue":"suppl 4","key":"10.1016\/j.esmogo.2024.100095_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2023.41.4_suppl.291","article-title":"Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 3-year follow-up from CheckMate 649","volume":"41","author":"Janjigian","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100095_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.annonc.2023.01.006","article-title":"VP1-2023: pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) cancer: phase III KEYNOTE-859 study","volume":"34","author":"Rha","year":"2023","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.esmogo.2024.100095_bib11","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1200\/JCO.23.00170","article-title":"Health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100095_bib12","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"10389","key":"10.1016\/j.esmogo.2024.100095_bib13","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal carcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100095_bib14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100095_bib15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","article-title":"FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival","volume":"29","author":"Ahn","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100095_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100095_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100095_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100095_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.esmogo.2024.100095_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"13","key":"10.1016\/j.esmogo.2024.100095_bib21","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100095_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10120-020-01153-6","article-title":"Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma","volume":"24","author":"Lordick","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.esmogo.2024.100095_bib23","doi-asserted-by":"crossref","unstructured":"Wyrwicz L, Elimova E, Blum SI, et\u00a0al. Health-related quality of life in patients with advanced gastric cancer\/gastroesophageal junction cancer or esophageal adenocarcinoma: results of nivolumab plus chemotherapy vs. chemotherapy from CheckMate 649. Poster presented at the American Society of Clinical Oncology conference. June 4-8, 2021; Chicago, IL, USA.","DOI":"10.1200\/JCO.2020.39.28_suppl.167"},{"issue":"suppl 4","key":"10.1016\/j.esmogo.2024.100095_bib24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.2023.41.4_suppl.286","article-title":"Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC)","volume":"41","author":"Moehler","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100095_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100189","article-title":"Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric\/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study","volume":"6","author":"Van Cutsem","year":"2021","journal-title":"ESMO Open"},{"issue":"16 suppl 1","key":"10.1016\/j.esmogo.2024.100095_bib26","article-title":"Trial in progress: phase 3 study of bemarituzumab\u00a0+ mFOLFOX6 versus placebo\u00a0+ mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) FGFR2b overexpression (FORTITUDE-101)","volume":"40","author":"Smyth","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100095_bib27","doi-asserted-by":"crossref","first-page":"TPS4165","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4165","article-title":"Trial in progress: phase 1b\/3 study of bemarituzumab\u00a0+ mFOLFOX6\u00a0+ nivolumab versus mFOLFOX6\u00a0+ nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102)","volume":"40","author":"Wainberg","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:27:41Z","timestamp":1753230461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"alternative-id":["S2949819824000566"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100095","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100095"}}